Importantly, Heymach et al. have reported that patients with non-small-cell lung cancer benefiting longer RFS from Vandetanib (anti-EGFR and anti-VEGRR2) monotherapy or in combination with chemotherapy result from the plasma IL-12 level not reduced after treatment35. This evidence concerns the gene EGFR and non-small cell lung carcinoma.